WASHINGTON — Pfizer has decided to leave the Biotechnology Innovation Organization, according to two sources familiar with the decision.
The departure is a blow to BIO, which represents members ranging from small biotech startups to massive pharmaceutical companies. The group on Tuesday announced its new CEO, rare disease advocate and biotech executive John Crowley.
Neither BIO nor Pfizer responded to requests for comment about the departure.
Study finds a significant relationship between the highest intake of ultra-processed foods, especially sweets, and an increased risk of developing glaucoma among Spanish university graduates,
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Issuer: Immunic, Inc. / Key word(s): Conference 29.02.2024 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic Presents Data